iData’s full report on the Global Interventional Cardiology Market includes in-depth information on the following segments:
- Coronary Atherectomy Devices
- Introducer Sheaths
- Vascular Closure
- Balloon Inflation
- CEP Devices
Overall, the global pandemic (COVID-19) resulted in a substantial decline in the global interventional cardiology market. The global interventional cardiology market, as most medical device markets, suffered a loss of 20% from 2019, resulting in a valuation of $11.1 billion in 2020. However, with 40% of the global interventional cardiology market share being controlled by Boston Scientific, Abbott and Medtronic, the overall market value is expected to reach $16.2 billion by 2027, with recovery expected to begin in 2022. At iData, we want to provide our clients with a top-level highlight of the three strongest market share holders as well as their product offerings to better analyze their market stance and advantages going into 2022.
TOP 3 MARKET LEADERS IN THE GLOBAL INTERVENTIONAL CARDIOLOGY MARKET
In 2020, Boston Scientific became the leading competitor in the global market for interventional cardiology devices. They are the market leaders in several segments such as: coronary balloon catheters, coronary embolic protection devices, and coronary atherectomy devices. Boston Scientific’s range of devices and additional products, such as the Maverick™, Apex™, and Emerge® PTCA devices, as well as the Flextome™ cutting balloon catheter, combined with their international sales team, has allowed them to maintain a dominant market position.
Following Boston Scientific, Abbott comes in as the second leader in the global interventional cardiology market. Abbott holds strong positions in the interventional coronary guidewire, coronary stent, FFR guidewire, and OCT catheter markets. Currently, Abbotts Xience™ DES is the most popular CTO-indicated line of coronary stents in the global market. Since their acquisition of St. Jude Medical in 2017, Abbott has extended their position in the overall market through the addition of coronary embolic protection devices, courtesy of St. Jude Medical.
Due to their presence in the coronary stent, coronary balloon catheter, and interventional coronary catheter markets, Medtronic comes in as the third leader within the global interventional cardiology market. With device offerings such as the Launcher® , Sherpa NX™, and Active & Sherpa NX™ Balanced product lines in their portfolio, Medtronic has earned their strong market holding through a mix of support, flexibility and ease of visualization that allows them to have products used in a wide variety of procedure sties.
GLOBAL INTERVENTIONAL CARDIOLOGY MARKET FURTHER INSIGHTS
For more information on unit sales, average selling prices (ASPs), competitive analyses, and more, follow the link below to receive a free market synopsis for the Global Interventional Cardiology Device Market Report.